Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy of dl-3-n-butylphthalide (NBP) and donepezil. Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease and other dementias. DL-3-n-butylphthalide is a synthetic compound originally derived from celery seed extract, with demonstrated effects on protecting mitochondria, improving microcirculation, reducing oxidative damage, and modulating glutamatergic neurotransmission. The combination has been studied for its potential synergistic effect in slowing cognitive decline and improving activities of daily living in patients with mild to moderate Alzheimer's disease as well as vascular dementia and post-stroke cognitive impairment[1][2][7]. Clinical studies suggest that this multi-target approach may offer greater benefit than either agent alone for these indications[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dl-3-n-butylphthalide + donepezil.